** Shares in Valneva VLS.PA jump 8.6% after brokerage Oddo BHF says it sees an attractive risk/reward on the stock ahead of the phase 3 results for its Lyme disease vaccine VLA15 expected in the coming weeks

** Valneva posted positive Phase 2 data in November 2025 showing strong efficacy and safety data for VLA15, prompting brokerage to find the risk/reward attractive and remark that the partnership with Pfizer secures operational execution

** "We anticipate peak sales of 1 billion euros ($1.18 billion) in 2035, based on a launch by Pfizer in 2027 in the US and Europe," Oddo BHF says

** "In a market segment with high potential and where competition remains non-existent, VLA15 thus occupies a unique position," broker adds

** Including session's rise, the stock has gained 14% YTD

($1 = 0.8460 euros)

(Reporting by Hugo Lhomedet)

((hugo.lhomedet@thomsonreuters.com))